YD Bio Ltd(YDES)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.6M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
YDES Stock Analysis & AI Quality Score
AI stock analysis and institutional research for YD Bio Ltd (YDES), a Healthcare sector company. YDES is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.6m in revenue. Based on the latest XBRL financial filings (FY 2025), YD Bio Ltd reports quarterly revenue of $596.8K, net income of $-8.3M, free cash flow of $-8.0M. Top institutional holders of YDES by reported 13-F value include Cypress Capital Management (WY), Oasis Management Co Ltd., GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. YDES trades on the Nasdaq exchange and files with the SEC under CIK 2011674. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate YDES daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for YD Bio Ltd directly from SEC EDGAR.
Revenue
FY 2025
$596.8K
Net Income
FY 2025
$-8.3M
Free Cash Flow
FY 2025
$-8.0M
D/E Ratio
FY 2025
0.00
AI Insight: YDES Financial Trends
YD Bio shows extremely limited financial data with negative equity of $3M as of Q4 2025.
• Equity deteriorated from $0M in Q2 2025 to negative $3M in Q4 2025.
• Total debt remained at $0M across both reported quarters.
⚠ Revenue and operating metrics remain unreported across all available periods.
AI Insight: YDES Ratio Trends
YD Bio Ltd shows no available financial ratio data across Q2 and Q4 2025, preventing trend analysis.
• All key financial ratios unavailable for Q2 2025 and Q4 2025 periods.
⚠ Complete absence of ratio data limits visibility into operational performance and financial health.
Get alerted when YDES's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for YD Bio Ltd including:
Top Institutional Holders of YDES
Cypress Capital Management LLC (WY)
$3.0M4,589,850 shOasis Management Co Ltd.
$770.0K100,000 shGEODE CAPITAL MANAGEMENT, LLC
$463.8K60,236 shCerity Partners LLC
$249.5K32,406 shCypress Capital Management LLC (WY)
$236.3K30,690 shCerity Partners LLC
$208.0K320,089 shCITADEL ADVISORS LLC
$149.8K19,450 shTrue North Advisors, LLC
$143.5K220,819 shUBS Group AG
$89.5K11,628 shClear Street Group Inc.
$66.5K102,358 sh
| Fund | Value | Shares |
|---|---|---|
| Cypress Capital Management LLC (WY) | $3.0M | 4,589,850 |
| Oasis Management Co Ltd. | $770.0K | 100,000 |
| GEODE CAPITAL MANAGEMENT, LLC | $463.8K | 60,236 |
| Cerity Partners LLC | $249.5K | 32,406 |
| Cypress Capital Management LLC (WY) | $236.3K | 30,690 |
| Cerity Partners LLC | $208.0K | 320,089 |
| CITADEL ADVISORS LLC | $149.8K | 19,450 |
| True North Advisors, LLC | $143.5K | 220,819 |
| UBS Group AG | $89.5K | 11,628 |
| Clear Street Group Inc. | $66.5K | 102,358 |
More Healthcare Companies
View all Healthcare →Put YDES on your watchlist
Track score changes the day YD Bio Ltd files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is YDES a good stock to buy?
13F Pro's AI-powered analysis of YD Bio Ltd (YDES) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for YDES are available on the YDES stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own YDES?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling YDES. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of YD Bio Ltd's investment landscape.